2012
Contribution of Endogenous Bradykinin to Fibrinolysis, Inflammation, and Blood Product Transfusion Following Cardiac Surgery: A Randomized Clinical Trial
Balaguer JM, Yu C, Byrne JG, Ball SK, Petracek MR, Brown NJ, Pretorius M. Contribution of Endogenous Bradykinin to Fibrinolysis, Inflammation, and Blood Product Transfusion Following Cardiac Surgery: A Randomized Clinical Trial. Clinical Pharmacology & Therapeutics 2012, 93: 326-334. PMID: 23361105, PMCID: PMC4031681, DOI: 10.1038/clpt.2012.249.Peer-Reviewed Original ResearchConceptsBradykinin B2 receptor antagonismB2 receptor antagonismCardiopulmonary bypassEndogenous bradykininTissue-type plasminogen activatorHoe 140Receptor antagonismBradykinin B2 receptor antagonistSubsequent transfusion requirementsBlood product transfusionProportion of patientsB2 receptor antagonistD-dimer concentrationD-dimer formationEACA treatmentTransfusion requirementsPostoperative bleedingProduct transfusionBlood lossCardiac surgeryInflammatory cytokinesReceptor antagonistClinical trialsFibrinolytic capacityInflammatory response
2003
Angiotensin-Converting Enzyme Inhibition Increases Human Vascular Tissue-Type Plasminogen Activator Release Through Endogenous Bradykinin
Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ. Angiotensin-Converting Enzyme Inhibition Increases Human Vascular Tissue-Type Plasminogen Activator Release Through Endogenous Bradykinin. Circulation 2003, 107: 579-585. PMID: 12566370, DOI: 10.1161/01.cir.0000046268.59922.a4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAngiotensin-Converting Enzyme InhibitorsBlood Flow VelocityBradykininBradykinin Receptor AntagonistsDose-Response Relationship, DrugEnalaprilatEndothelium, VascularFemaleFibrinolysisForearmHumansInfusions, Intra-ArterialMaleMethacholine ChlorideMuscarinic AgonistsRegional Blood FlowSmokingTissue Plasminogen ActivatorVascular ResistanceConceptsForearm blood flowNet t-PA releaseT-PA releaseEndothelial t-PA releaseHoe 140T-PA responseEndogenous bradykininACE inhibitionExogenous bradykininTissue-type plasminogen activator releaseReceptor antagonist HOE 140Angiotensin-Converting Enzyme InhibitionBradykinin receptor antagonist HOE 140Effects of enalaprilatIntra-arterial enalaprilatIntra-arterial infusionPlasminogen activator releaseEnzyme inhibitionFBF responseVascular resistanceBlood flowActivator releaseEnalaprilatBradykininMethacholine
2000
Bradykinin Stimulates Tissue Plasminogen Activator Release From Human Forearm Vasculature Through B2 Receptor–Dependent, NO Synthase–Independent, and Cyclooxygenase-Independent Pathway
Brown N, Gainer J, Murphey L, Vaughan D. Bradykinin Stimulates Tissue Plasminogen Activator Release From Human Forearm Vasculature Through B2 Receptor–Dependent, NO Synthase–Independent, and Cyclooxygenase-Independent Pathway. Circulation 2000, 102: 2190-2196. PMID: 11056091, DOI: 10.1161/01.cir.102.18.2190.Peer-Reviewed Original ResearchMeSH Keywords6-Ketoprostaglandin F1 alphaAcetylcholineAdrenergic beta-AntagonistsAdultBradykininBradykinin Receptor AntagonistsCyclooxygenase InhibitorsEndothelium, VascularFemaleForearmHumansIndomethacinInfusions, Intra-ArterialMaleNitric Oxide SynthaseNitroprussideOmega-N-MethylargininePlethysmographyReceptor, Bradykinin B2Regional Blood FlowTissue Plasminogen ActivatorVasodilationVasodilator AgentsConceptsTissue plasminogen activator releaseVasodilator responseL-NMMAPlasminogen activator releaseCyclooxygenase-independent pathwayTPA releaseActivator releaseBasal forearm blood flowReceptor antagonist HOE 140NO synthase inhibitor LHuman endotheliumHuman forearm vasculatureForearm blood flowEffect of indomethacinIntra-arterial bradykininReceptor-dependent effectsCyclooxygenase inhibitor indomethacinMonomethyl-L-arginineForearm vasodilationEndothelial effectsIndomethacin administrationForearm vasculatureHoe 140Receptor antagonismUrinary excretion
1998
Effect of Bradykinin-Receptor Blockade on the Response to Angiotensin-Converting–Enzyme Inhibitor in Normotensive and Hypertensive Subjects
Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of Bradykinin-Receptor Blockade on the Response to Angiotensin-Converting–Enzyme Inhibitor in Normotensive and Hypertensive Subjects. New England Journal Of Medicine 1998, 339: 1285-1292. PMID: 9791144, DOI: 10.1056/nejm199810293391804.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureBradykininBradykinin Receptor AntagonistsCaptoprilDiet, Sodium-RestrictedDrug InteractionsDrug Therapy, CombinationFemaleHumansHypertensionKidneyLosartanMaleReference ValuesRenin-Angiotensin SystemSingle-Blind MethodConceptsPlasma renin activityBlood pressureACE inhibitionHypertensive subjectsShort-term effectsRenin activitySpecific bradykinin receptor antagonistAngiotensin converting enzyme (ACE) inhibitorsAdministration of captoprilAdministration of losartanBradykinin receptor blockadeCoadministration of icatibantContribution of bradykininRenal hemodynamic responseNormal blood pressureRenin-angiotensin systemSeparate study daysBradykinin receptor antagonistDegradation of bradykininAntagonist losartanHypertensive personsHypotensive effectAngiotensin IIAngiotensin-ConvertingHemodynamic response